Jiangsu Hengrui Pharmaceuticals Co Ltd

Jiangsu Hengrui Pharmaceuticals’ breakthrough therapy approval boosts its oncology pipeline, spurs rapid market entry, and underpins a solid, shareholder‑friendly growth strategy.

Jiangsu Hengrui Pharma’s SHR‑1049 injection clinical trial receives NMPA approval, marking a new anti‑tumor candidate and a positive sign for investors.

Hengrui’s Ruilafupa‑α injection gains NMPA approval, boosting its oncology portfolio, investor confidence, and positioning the company for rapid growth and global expansion.

Discover how Jiangsu Hengrui’s breakthrough ADC, SHR‑A1904, is reshaping oncology in China – a game‑changing investment in targeted cancer therapy.

Jiangsu Hengrui’s new CFDA approvals for six oncology and autoimmune drugs boost its pipeline depth and investor confidence, positioning the firm for Phase‑III success and higher earnings.

Explore Jiangsu Hengrui’s 2025 momentum: strong anti‑cancer drugs, buy‑back signals, and margin gains position it as a top Chinese pharma stock.

Jiangsu Hengrui Pharmaceuticals posts 13.7% revenue growth, 24.5% profit surge, and receives JPMorgan Overweight upgrade amid China’s new drug‑insurance policy.

Jiangsu Hengrui Pharmaceuticals Co Ltd has reported robust growth in its latest earnings, with a 13.4% increase in revenue and a 43.9% rise in net income, leading to an upgrade by JPMorgan to an ‘Overweight’ rating, citing sustained revenue momentum…